CO
Coward_Nutlick
Community Contributor
Member since 2025
Views471Total number of views
Followers11Total number of followers
Comments0Total number of comments
Former Silicon Valley Biotech Venture Capitalist
No link added
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
320
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
CO
US$40
27.4% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Revenue
35.69% p.a.
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
146
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
CO
US$95
91.6% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$0